Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
June 19th @ 10 am Eastern Most who particpate in AnCan's programs know we are massive proponents of involving palliative care, or as UCSF calls it 'Symptom Management'', early in your treatment path - so we stronlgly recommend attending this CureTalk webinar. Dr. Mike is a good friend of AnCan, as is CureTalk - so […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
This group is for men with complex disease either at diagnosis, or whose disease has recurred with or without evidence of metastasis. With men who have experienced the gamut of treatments, we discuss status, as well as new developments in treatment and technology. New participants are given priority to discuss their situation. 1st & 3rd Mondays […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Episode 1 of 3 in Your Prostate Cancer Questions Answered. In 2018, patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) were watching and waiting. Two years later there are three novel androgen receptor inhibitors available. But more options mean more questions for doctors and for patients. In this first installment of our prostate cancer Answers Now series, we’ll explore these […]
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated D Grade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
